Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Abstract EN

Objective.

Current studies of serum sclerostin levels in AS and RA patients are inconsistent.

This meta-analysis was performed to identify the association of serum sclerostin level with AS and RA patients.

Methods.

Embase, PubMed, MEDLINE, and Cochrane Library databases (up to 25 January 2017) were used to collect all relevant published articles.

Studies were pooled and standard mean difference (SMD) with 95% confidence interval (CI) was calculated.

All data analyses were performed using RevMan 5.3.

Results.

Totally eight studies of AS including 420 AS patients and 317 healthy controls (HC) and three studies of RA including 145 RA patients and 127 HC were finally included in this meta-analysis.

The results revealed that the serum sclerostin levels in both AS patients (SMD=-0.14; 95% CI=[-0.39,0.11]; P=0.28) and RA patients (SMD=-0.10; 95% CI=[-0.34,0.15]; P=0.43) were not significantly different from those in HC.

Conclusion.

The difference of serum sclerostin levels in AS and RA patients was not significantly different from HC, indicating that the sclerostin may not associate with the development of AS and RA.